European Code against Cancer 4th Edition: Infections and Cancer

Cancer Epidemiology

Volumn 39, Issue , 2015, Pages S120-S138

  Villain, Patricia ^a   Gonzalez, Paula ^a,d   Almonte, Maribel ^a   Franceschi, Silvia ^a   Dillner, Joakim ^b   Anttila, Ahti ^c   Park, Jin Young ^a   De Vuyst, Hugo ^a   Herrero, Rolando ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

^c FINNISH CANCER REGISTRY   (Finland)

^d Proyecto Epidemiológico Guanacaste   (Sierra Leone)

Author keywords

Cancer vaccines; Cervical cancer; Europe; Gastric cancer; Helicobacter pylori; Hepatitis B vaccines; Hepatitis B C treatments; Hepatocellular carcinoma (HCC); HIV; Human papillomavirus vaccines

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS C VACCINE; WART VIRUS VACCINE;

ARTICLE; CANCER PREVENTION; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; COUNSELING; DISEASE ASSOCIATION; EUROPEAN CODE AGAINST CANCER; EUROPEAN UNION; HEALTH CARE PERSONNEL; HELICOBACTER PYLORI; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INFECTION; NEOPLASM; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK REDUCTION; VACCINATION; WART VIRUS; COMPLICATION; NEOPLASMS; RISK FACTOR; STANDARDS;

EUROPEAN UNION; HUMANS; INFECTION; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84977454006     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2015.10.006     Document Type: Article

References (167)

1. [1] De Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D., Plummer, M., Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13 (2012), 607–615.
2. [2] Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J.W., Comber, H., Forman, D., Bray, F., Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49 (2013), 1374–1403.
3. [3] IARC, Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B: A Review of Human Carcinogens: Biological Agents, (2012).
4. [4] Forman, D., de, M.C., Lacey, C.J., Soerjomataram, I., Lortet-Tieulent, J., Bruni, L., Vignat, J., Ferlay, J., Bray, F., Plummer, M., Franceschi, S., Global burden of human papillomavirus and related diseases. Vaccine 30:Suppl. 5 (2012), F12–F23.
5. [5] Li, N., Franceschi, S., Howell-Jones, R., Snijders, P.J., Clifford, G.M., Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer 128 (2011), 927–935.
6. [6] Alemany, L., Saunier, M., Tinoco, L., Quiros, B., Alvarado-Cabrero, I., Alejo, M., Joura, E.A., Maldonado, P., Klaustermeier, J., Salmeron, J., Bergeron, C., Petry, K.U., Guimera, N., Clavero, O., Murillo, R., Clavel, C., Wain, V., Geraets, D.T., Jach, R., Cross, P., Carrilho, C., Molina, C., Shin, H.R., Mandys, V., Nowakowski, A.M., Vidal, A., Lombardi, L., Kitchener, H., Sica, A.R., Magana-Leon, C., Pawlita, M., Quint, W., Bravo, I.G., Munoz, N., de, S.S., Bosch, F.X., Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur. J. Cancer 50 (2014), 2846–2854.
7. [7] Alemany, L., Saunier, M., Alvarado-Cabrero, I., Quiros, B., Salmeron, J., Shin, H.R., Pirog, E.C., Guimera, N., Hernandez-Suarez, G., Felix, A., Clavero, O., Lloveras, B., Kasamatsu, E., Goodman, M.T., Hernandez, B.Y., Laco, J., Tinoco, L., Geraets, D.T., Lynch, C.F., Mandys, V., Poljak, M., Jach, R., Verge, J., Clavel, C., Ndiaye, C., Klaustermeier, J., Cubilla, A., Castellsague, X., Bravo, I.G., Pawlita, M., Quint, W.G., Munoz, N., Bosch, F.X., de, S.S., Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int. J. Cancer 136 (2015), 98–107.
8. [8] Miralles-Guri, C., Bruni, L., Cubilla, A.L., Castellsague, X., Bosch, F.X., de, S.S., Human papillomavirus prevalence and type distribution in penile carcinoma. J. Clin. Pathol. 62 (2009), 870–878.
9. [9] Herrero, R., Castellsague, X., Pawlita, M., Lissowska, J., Kee, F., Balaram, P., Rajkumar, T., Sridhar, H., Rose, B., Pintos, J., Fernandez, L., Idris, A., Sanchez, M.J., Nieto, A., Talamini, R., Tavani, A., Bosch, F.X., Reidel, U., Snijders, P.J., Meijer, C.J., Viscidi, R., Munoz, N., Franceschi, S., Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J. Natl. Cancer Inst. 95 (2003), 1772–1783.
10. [10] Gillison, M.L., Alemany, L., Snijders, P.J., Chaturvedi, A., Steinberg, B.M., Schwartz, S., Castellsague, X., Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 30:Suppl. 5 (2012), F34–F54.
11. [11] Bosch, F.X., Tsu, V., Vorsters, A., Van, D.P., Kane, M.A., Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine 30:Suppl. 5 (2012), F1–11.
12. [12] Moscicki, A.B., Schiffman, M., Kjaer, S., Villa, L.L., Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine, 24(Suppl. 3), 2006 S3-42–S3-51.
13. [13] Moscicki, A.B., Schiffman, M., Burchell, A., Albero, G., Giuliano, A.R., Goodman, M.T., Kjaer, S.K., Palefsky, J., Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30:Suppl. 5 (2012), F24–F33.
14. [14] Appleby, P., Beral, V., Berrington de, G.A., Colin, D., Franceschi, S., Goodill, A., Green, J., Peto, J., Plummer, M., Sweetland, S., Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int. J. Cancer 118 (2006), 1481–1495.
15. [15] Appleby, P., Beral, V., Berrington de, G.A., Colin, D., Franceschi, S., Goodhill, A., Green, J., Peto, J., Plummer, M., Sweetland, S., Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370 (2007), 1609–1621.
16. [16] Castellsague, X., Pawlita, M., Roura, E., Margall, N., Waterboer, T., Bosch, F.X., de, S.S., Gonzalez, C.A., Dillner, J., Gram, I.T., Tjonneland, A., Munk, C., Pala, V., Palli, D., Khaw, K.T., Barnabas, R.V., Overvad, K., Clavel-Chapelon, F., Boutron-Ruault, M.C., Fagherazzi, G., Kaaks, R., Lukanova, A., Steffen, A., Trichopoulou, A., Trichopoulos, D., Klinaki, E., Tumino, R., Sacerdote, C., Mattiello, A., Bueno-de-Mesquita, H.B., Peeters, P.H., Lund, E., Weiderpass, E., Quiros, J.R., Sanchez, M.J., Navarro, C., Barricarte, A., Larranaga, N., Ekstrom, J., Hortlund, M., Lindquist, D., Wareham, N., Travis, R.C., Rinaldi, S., Tommasino, M., Franceschi, S., Riboli, E., Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: evidence from the EPIC cohort. Int. J. Cancer 135 (2014), 440–452.
17. [17] IARC, Cervix Cancer Screening, IARC Handbooks of Cancer Prevention, vol. 10, 2005, IARC Press, Lyon, 1–302.
18. [18] Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2013, International Agency for Research on Cancer, Lyon, France Available from: http://globocan.iarc.fr (accessed on 26.03.2015).
19. [19] Schiller, J.T., Castellsague, X., Garland, S.M., A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30:Suppl. 5 (2012), F123–F138.
20. [20] World Health Organization, Human papillomavirus vaccines. WHO Position Paper, Wkly Epidemiol Rec. 84 (2009), 118–131.
21. [21] Pedersen, C., Petaja, T., Strauss, G., Rumke, H.C., Poder, A., Richardus, J.H., Spiessens, B., Descamps, D., Hardt, K., Lehtinen, M., Dubin, G., Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health 40 (2007), 564–571.
22. [22] Block, S.L., Nolan, T., Sattler, C., Barr, E., Giacoletti, K.E., Marchant, C.D., Castellsague, X., Rusche, S.A., Lukac, S., Bryan, J.T., Cavanaugh, P.F. Jr, Reisinger, K.S., Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (2006), 2135–2145.
23. [23] Perez, G., Lazcano-Ponce, E., Hernandez-Avila, M., Garcia, P.J., Munoz, N., Villa, L.L., Bryan, J., Taddeo, F.J., Lu, S., Esser, M.T., Vuocolo, S., Sattler, C., Barr, E., Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int. J. Cancer 122 (2008), 1311–1318.
24. [24] World Health Organization, Human papillomavirus vaccines: WHO position paper, October 2014. Wkly. Epidemiol. Rec. 89 (2014), 465–491.
25. [25] Lu, B., Kumar, A., Castellsague, X., Giuliano, A.R., Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect. Dis., 11, 2011, 13.
26. [26] Malagon, T., Drolet, M., Boily, M.C., Franco, E.L., Jit, M., Brisson, J., Brisson, M., Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12 (2012), 781–789.
27. [27] Petaja, T., Keranen, H., Karppa, T., Kawa, A., Lantela, S., Siitari-Mattila, M., Levanen, H., Tocklin, T., Godeaux, O., Lehtinen, M., Dubin, G., Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years. J. Adolesc. Health 44 (2009), 33–40.
28. [28] Giuliano, A.R., Palefsky, J.M., Goldstone, S., Moreira, E.D. Jr., Penny, M.E., Aranda, C., Vardas, E., Moi, H., Jessen, H., Hillman, R., Chang, Y.H., Ferris, D., Rouleau, D., Bryan, J., Marshall, J.B., Vuocolo, S., Barr, E., Radley, D., Haupt, R.M., Guris, D., Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N. Engl. J. Med. 364 (2011), 401–411.
29. [29] Moreira, E.D. Jr., Palefsky, J.M., Giuliano, A.R., Goldstone, S., Aranda, C., Jessen, H., Hillman, R.J., Ferris, D., Coutlee, F., Vardas, E., Marshall, J.B., Vuocolo, S., Haupt, R.M., Guris, D., Garner, E.I., Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum. Vaccine 7 (2011), 768–775.
30. [30] Palefsky, J.M., Giuliano, A.R., Goldstone, S., Moreira, E.D. Jr., Aranda, C., Jessen, H., Hillman, R., Ferris, D., Coutlee, F., Stoler, M.H., Marshall, J.B., Radley, D., Vuocolo, S., Haupt, R.M., Guris, D., Garner, E.I., HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 365 (2011), 1576–1585.
31. [31] Hillman, R.J., Giuliano, A.R., Palefsky, J.M., Goldstone, S., Moreira, E.D. Jr., Vardas, E., Aranda, C., Jessen, H., Ferris, D.G., Coutlee, F., Marshall, J.B., Vuocolo, S., Haupt, R.M., Guris, D., Garner, E.I., Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin. Vaccine Immunol. 19 (2012), 261–267.
32. [32] Goldstone, S.E., Jessen, H., Palefsky, J.M., Giuliano, A.R., Moreira, E.D. Jr, Vardas, E., Aranda, C., Hillman, R.J., Ferris, D.G., Coutlee, F., Marshall, J.B., Vuocolo, S., Haupt, R.M., Guris, D., Garner, E., Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine 31 (2013), 3849–3855.
33. [33] Kjaer, S.K., Sigurdsson, K., Iversen, O.E., Hernandez-Avila, M., Wheeler, C.M., Perez, G., Brown, D.R., Koutsky, L.A., Tay, E.H., Garcia, P., Ault, K.A., Garland, S.M., Leodolter, S., Olsson, S.E., Tang, G.W., Ferris, D.G., Paavonen, J., Lehtinen, M., Steben, M., Bosch, F.X., Dillner, J., Joura, E.A., Majewski, S., Munoz, N., Myers, E.R., Villa, L.L., Taddeo, F.J., Roberts, C., Tadesse, A., Bryan, J., Maansson, R., Lu, S., Vuocolo, S., Hesley, T.M., Saah, A., Barr, E., Haupt, R.M., A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. (Phila) 2 (2009), 868–878.
34. [34] Munoz, N., Kjaer, S.K., Sigurdsson, K., Iversen, O.E., Hernandez-Avila, M., Wheeler, C.M., Perez, G., Brown, D.R., Koutsky, L.A., Tay, E.H., Garcia, P.J., Ault, K.A., Garland, S.M., Leodolter, S., Olsson, S.E., Tang, G.W., Ferris, D.G., Paavonen, J., Steben, M., Bosch, F.X., Dillner, J., Huh, W.K., Joura, E.A., Kurman, R.J., Majewski, S., Myers, E.R., Villa, L.L., Taddeo, F.J., Roberts, C., Tadesse, A., Bryan, J.T., Lupinacci, L.C., Giacoletti, K.E., Sings, H.L., James, M.K., Hesley, T.M., Barr, E., Haupt, R.M., Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl. Cancer Inst. 102 (2010), 325–339.
35. [35] Herrero, R., Wacholder, S., Rodriguez, A.C., Solomon, D., Gonzalez, P., Kreimer, A.R., Porras, C., Schussler, J., Jimenez, S., Sherman, M.E., Quint, W., Schiller, J.T., Lowy, D.R., Schiffman, M., Hildesheim, A., Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 1 (2011), 408–419.
36. [36] Lehtinen, M., Paavonen, J., Wheeler, C.M., Jaisamrarn, U., Garland, S.M., Castellsague, X., Skinner, S.R., Apter, D., Naud, P., Salmeron, J., Chow, S.N., Kitchener, H., Teixeira, J.C., Hedrick, J., Limson, G., Szarewski, A., Romanowski, B., Aoki, F.Y., Schwarz, T.F., Poppe, W.A., De Carvalho, N.S., Germar, M.J., Peters, K., Mindel, A., De, S.P., Bosch, F.X., David, M.P., Descamps, D., Struyf, F., Dubin, G., Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13 (2012), 89–99.
37. [37] Rodriguez, A.C., Solomon, D., Herrero, R., Hildesheim, A., Gonzalez, P., Wacholder, S., Porras, C., Jimenez, S., Schiffman, M., Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am. J. Epidemiol. 178 (2013), 752–760.
38. [38] McCormack, P.L., Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil((R))): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. Drugs 74 (2014), 1253–1283.
39. [39] Castellsague, X., Munoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K., Luna, J., Myers, E., Mallary, S., Bautista, O.M., Bryan, J., Vuocolo, S., Haupt, R.M., Saah, A., End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br. J. Cancer 105 (2011), 28–37.
40. [40] Skinner, S.R., Szarewski, A., Romanowski, B., Garland, S.M., Lazcano-Ponce, E., Salmeron, J., Del Rosario-Raymundo, M.R., Verheijen, R.H., Quek, S.C., da Silva, D.P., Kitchener, H., Fong, K.L., Bouchard, C., Money, D.M., Ilancheran, A., Cruickshank, M.E., Levin, M.J., Chatterjee, A., Stapleton, J.T., Martens, M., Quint, W., David, M.P., Meric, D., Hardt, K., Descamps, D., Geeraerts, B., Struyf, F., Dubin, G., Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 384 (2014), 2213–2227.
41. [41] Kreimer, A.R., Gonzalez, P., Katki, H.A., Porras, C., Schiffman, M., Rodriguez, A.C., Solomon, D., Jimenez, S., Schiller, J.T., Lowy, D.R., van Doorn, L.J., Struijk, L., Quint, W., Chen, S., Wacholder, S., Hildesheim, A., Herrero, R., Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 12 (2011), 862–870.
42. [42] Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H.A., Porras, C., Schiffman, M., Rodriguez, A.C., Solomon, D., Jimenez, S., Schiller, J.T., Lowy, D.R., van Doorn, L.J., Wacholder, S., Kreimer, A.R., Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One, 8, 2013, e68329.
43. [43] Lang Kuhs, K.A., Gonzalez, P., Rodriguez, A.C., van Doorn, L.J., Schiffman, M., Struijk, L., Chen, S., Quint, W., Lowy, D.R., Porras, C., DelVecchio, C., Jimenez, S., Safaeian, M., Schiller, J.T., Wacholder, S., Herrero, R., Hildesheim, A., Kreimer, A.R., Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica vaccine trial. J. Infect. Dis. 210 (2014), 1890–1899.
44. [44] Paavonen, J., Naud, P., Salmeron, J., Wheeler, C.M., Chow, S.N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J.C., Skinner, S.R., Hedrick, J., Jaisamrarn, U., Limson, G., Garland, S., Szarewski, A., Romanowski, B., Aoki, F.Y., Schwarz, T.F., Poppe, W.A., Bosch, F.X., Jenkins, D., Hardt, K., Zahaf, T., Descamps, D., Struyf, F., Lehtinen, M., Dubin, G., Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 (2009), 301–314.
45. [45] Wheeler, C.M., Kjaer, S.K., Sigurdsson, K., Iversen, O.E., Hernandez-Avila, M., Perez, G., Brown, D.R., Koutsky, L.A., Tay, E.H., Garcia, P., Ault, K.A., Garland, S.M., Leodolter, S., Olsson, S.E., Tang, G.W., Ferris, D.G., Paavonen, J., Steben, M., Bosch, F.X., Dillner, J., Joura, E.A., Kurman, R.J., Majewski, S., Munoz, N., Myers, E.R., Villa, L.L., Taddeo, F.J., Roberts, C., Tadesse, A., Bryan, J., Lupinacci, L.C., Giacoletti, K.E., James, M., Vuocolo, S., Hesley, T.M., Barr, E., The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 199 (2009), 936–944.
46. [46] Macartney, K.K., Chiu, C., Georgousakis, M., Brotherton, J.M., Safety of human papillomavirus vaccines: a review. Drug Safety 36 (2013), 393–412.
47. [47] Block, S.L., Brown, D.R., Chatterjee, A., Gold, M.A., Sings, H.L., Meibohm, A., Dana, A., Haupt, R.M., Barr, E., Tamms, G.M., Zhou, H., Reisinger, K.S., Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr. Infect. Dis. J. 29 (2010), 95–101.
48. [48] Angelo, M.G., David, M.P., Zima, J., Baril, L., Dubin, G., Arellano, F., Struyf, F., Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol. Drug Safety 23 (2014), 466–479.
49. [49] Bonhoeffer, J., Black, S., Izurieta, H., Zuber, P., Sturkenboom, M., Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe. Biologicals 40 (2012), 393–397.
50. [50] MHRA (Medicines and Healthcare Products Regulatory Agency). Yellow Card Scheme. 2014 Available from https://yellowcard.mhra.gov.uk/ (acessed on 26.02.2015).
51. [51] Angelo, M.G., Zima, J., Tavares Da, S.F., Baril, L., Arellano, F., Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiol. Drug Safety 23 (2014), 456–465.
52. [52] Slade, B.A., Leidel, L., Vellozzi, C., Woo, E.J., Hua, W., Sutherland, A., Izurieta, H.S., Ball, R., Miller, N., Braun, M.M., Markowitz, L.E., Iskander, J., Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302 (2009), 750–757.
53. [53] Institute of Medicine of the National Academies. Adverse Effects of Vaccines: Evidence and Causality., 2011 Available from: http://iom.nationalacademies.org/Reports/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality.aspx (accessed on 27.03.2015).
54. [54] Global Advisory Committee on Vaccine Safety (GACVS). Statement on the Continued Safety of HPV Vaccination. 2014 Available from: http://www.who.int/vaccine_safety/committee/topics/hpv/GACVS_Statement_HPV_12_Mar_2014.pdf (accessed on 26.03.2015).
55. [55] Gaudelus, J., Cohen, R., Martinot, A., Stahl, J.P., Lery, T., Le, D.M., Denis, F., [HPV vaccination is still difficult to implement]. Med. Mal. Infect. 44 (2014), 289–291.
56. [56] Ferris, D., Samakoses, R., Block, S.L., Lazcano-Ponce, E., Restrepo, J.A., Reisinger, K.S., Mehlsen, J., Chatterjee, A., Iversen, O.E., Sings, H.L., Shou, Q., Sausser, T.A., Saah, A., Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics 134 (2014), e657–e665.
57. [57] Tabrizi, S.N., Brotherton, J.M., Kaldor, J.M., Skinner, S.R., Cummins, E., Liu, B., Bateson, D., McNamee, K., Garefalakis, M., Garland, S.M., Fall in human papillomavirus prevalence following a national vaccination program. J. Infect. Dis 206 (2012), 1645–1651.
58. [58] Read, T.R., Hocking, J.S., Chen, M.Y., Donovan, B., Bradshaw, C.S., Fairley, C.K., The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm. Infect. 87 (2011), 544–547.
59. [59] Brotherton, J.M., Fridman, M., May, C.L., Chappell, G., Saville, A.M., Gertig, D.M., Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377 (2011), 2085–2092.
60. [60] Leval, A., Herweijer, E., Ploner, A., Eloranta, S., Fridman, S.J., Dillner, J., Young, C., Netterlid, E., Sparen, P., Arnheim-Dahlstrom, L., Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J. Natl. Cancer Inst. 105 (2013), 469–474.
61. [61] U.S. Food and Drug Administration (FDA). Human Papillomavirus 9-valent Vaccine (Gardasil 9). 2015 Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm426445.htm (accessed on 25.03.2015).
62. [62] European Medicines Agency (EMA), Summary of the European Public Assessment Report (EPAR) for Gardasil 9., 2015 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003852/human_med_001863.jsp (accessed on 05.08.2015).
63. [63] Anttila, A., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S., Patnick, J., Ronco, G., Segnan, N., Suonio, E., Törnberg, S., von Karsa, L., (eds.) European Guidelines for Quality Assurance in Cervical Cancer Screening, Second edition, Supplements, 2015, Office for Official Publications of the European Union, Luxembourg.
64. [64] Kreimer, A.R., Rodriguez, A.C., Hildesheim, A., Herrero, R., Porras, C., Schiffman, M., Gonzalez, P., Solomon, D., Jimenez, S., Schiller, J.T., Lowy, D.R., Quint, W., Sherman, M.E., Schussler, J., Wacholder, S., Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J. Natl. Cancer Inst. 103 (2011), 1444–1451.
65. [65] Lazcano-Ponce, E., Stanley, M., Munoz, N., Torres, L., Cruz-Valdez, A., Salmeron, J., Rojas, R., Herrero, R., Hernandez-Avila, M., Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 32 (2014), 725–732.
66. [66] Dobson, S.R., McNeil, S., Dionne, M., Dawar, M., Ogilvie, G., Krajden, M., Sauvageau, C., Scheifele, D.W., Kollmann, T.R., Halperin, S.A., Langley, J.M., Bettinger, J.A., Singer, J., Money, D., Miller, D., Naus, M., Marra, F., Young, E., Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 309 (2013), 1793–1802.
67. [67] D'Addario, M., Scott, P., Redmond, S., Low, N., HPV vaccines: systematic review of literature on alternative vaccination schedules, in: Evidence-based recommendations on human papillomavirus (HPV) schedules: Background paper for SAGE discussions. World Health Organization, Geneva, 2014.
68. [68] De Vuyst, H., Howell-Jones, R., Levy-Bruhl, D., Giorgi Rossi, P., Franceschi, S., Implementation of vaccination against human papillomavirus in Europe (S3). Anttila, A., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S., Patnick, J., Ronco, G., Segnan, N., Suonio, E., Törnberg, S., von Karsa, L., (eds.) European Guidelines for Quality Assurance in Cervical Cancer Screening, Second edition, Supplements, 2015, Office for Official Publications of the European Union, Luxembourg.
69. [69] Elfstrom, K.M., Dillner, J., Arnheim-Dahlstrom, L., Organization and quality of HPV vaccination programs in Europe. Vaccine 33 (2015), 1673–1681.
70. [70] Owsianka, B., Ganczak, M., Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide. Przegl. Epidemiol. 69 (2015), 53–55.
71. [71] Baussano, I., Dillner, J., Lazzarato, F., Ronco, G., Franceschi, S., Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect. Agent Cancer, 9, 2014, 4.
72. [72] European Medicines Agency (EMA). Summary of the European Public Assessment Report (EPAR) for Cervarix., 2015 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124 (accessed on 27.03.2015).
73. [73] European Medicines Agency (EMA). Summary of the European Public Assessment Report (EPAR) for Gardasil., 2015 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp&mid=WC0b01ac058001d124 (accessed on 27.03.2015).
74. [74] European Centre for Disease Prevention and Control. Introduction of HPV Vaccines in EU countries – An Update. 2012 Available from: http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=677 (accessed on 03.11.2015).
75. [75] Westra, T.A., Rozenbaum, M.H., Rogoza, R.M., Nijman, H.W., Daemen, T., Postma, M.J., Wilschut, J.C., Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J. Infect. Dis. 204 (2011), 377–384.
76. [76] Rodriguez, E.F., Reynolds, J.P., Jenkins, S.M., Winter, S.M., Henry, M.R., Nassar, A., Atypical squamous cells of undetermined significance in patients with HPV positive DNA testing and correlation with disease progression by age group: an institutional experience. Int. J. Clin. Exp. Pathol. 5 (2012), 428–435.
77. [77] PBAC (The Pharmaceutical Benefits Advisory Committee)-Australian Government (Depatment of Health). November 2011 PBAC Meeting Outcomes – Positive Recommendations. 2011 Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/2011-11/positive-recommendations (accessed on 27.03.2015).
78. [78] NACI (National Advisory Committee on Immunization). Update on Human Papillomavirus (HPV) Vaccines (an Advisory Committee Statement), Canada Communicable Disease Report (CCDR), vol. 38, 2012 Available from: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/assets/pdf/12vol-38-acs-dcc-1-eng.pdf (accessed on 26.03.2015).
79. [79] CDC (Centers for Disease Control and Prevention). Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). 2014 Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6305a1.htm (accessed on 26.03.2015).
80. [80] Giuliano, A.R., Nyitray, A.G., Kreimer, A.R., Pierce Campbell, C.M., Goodman, M.T., Sudenga, S.L., Monsonego, J., Franceschi, S., EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int. J. Cancer 136 (2015), 2752–2760.
81. [81] IARC. The European Code Against Cancer (ECAC). 2014 Available from: http://cancer-code-europe.iarc.fr (accessed on 12.03.2015).
82. [82] Franceschi, S., Herrero, R., Infections. Stewart, B.W., Wild, C.P., (eds.) World Cancer Report 2014, International Agency for Research on Cancer, 2014, 105–114.
83. [83] Theise, N.D., Liver cancer. Stewart, B.W., Wild, C.P., (eds.) World Cancer Report 2014, 2014, International Agency for Research on Cancer, 105–114.
84. [84] Chen, C.J., Chen, W., Franceschi, S., Hall, S.A., London, W.T., McGlynn, K.A., Wild, C.P., Gelband, H., Liver Cancer. Gelband, H., Jha, P., Sankaranarayanan, R., Horton, S., (eds.) Cancer, 2014, University of Washington, Department of Global Health, Seattle.
85. [85] El-Serag, H.B., Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142 (2012), 1264–1273.e1.
86. [86] Forghieri, F., Luppi, M., Barozzi, P., Maffei, R., Potenza, L., Narni, F., Marasca, R., Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. Clin. Dev. Immunol., 2012(807351), 2012.
87. [87] Boffetta, P., Hashibe, M., La, V.C., Zatonski, W., Rehm, J., The burden of cancer attributable to alcohol drinking. Int. J. Cancer 119 (2006), 884–887.
88. [88] Raza, S.A., Clifford, G.M., Franceschi, S., Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br. J. Cancer 96 (2007), 1127–1134.
89. [89] Hahne, S.J., Veldhuijzen, I.K., Wiessing, L., Lim, T.A., Salminen, M., Laar, M., Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect. Dis., 13, 2013, 181.
90. [90] Hope, V.D., Eramova, I., Capurro, D., Donoghoe, M.C., Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol. Infect. 142 (2014), 270–286.
91. [91] European Centre for Disease Prevention and Control, Assessing the Burden of Key Infectious Diseases Affecting Migrant Populations in the EU/EEA. 2014 Available from: http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1099 (accessed on 03.11.2015).
92. [92] Hatzakis, A., Van, D.P., Alcorn, K., Gore, C., Benazzouz, M., Berkane, S., Buti, M., Carballo, M., Cortes, M.H., Deuffic-Burban, S., Dominguez, A., Donoghoe, M., Elzouki, A.N., Ben-Alaya, B.N., Esmat, G., Esteban, R., Fabri, M., Fenton, K., Goldberg, D., Goulis, I., Hadjichristodoulou, C., Hatzigeorgiou, T., Hamouda, O., Hasurdjiev, S., Hughes, S., Kautz, A., Malik, M., Manolakopoulos, S., Maticic, M., Papatheodoridis, G., Peck, R., Peterle, A., Potamitis, G., Prati, D., Roudot-Thoraval, F., Reic, T., Sharara, A., Shennak, M., Shiha, G., Shouval, D., Socan, M., Thomas, H., Thursz, M., Tosti, M., Trepo, C., Vince, A., Vounou, E., Wiessing, L., Manns, M., The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J. Viral. Hepat. 20:Suppl. 2 (2013), 1–20.
93. [93] Tarocchi, M., Polvani, S., Marroncini, G., Galli, A., Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J. Gastroenterol. 20 (2014), 11630–11640.
94. [94] Gower, E., Estes, C.C., Hindman, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol., 2014.
95. [95] Arzumanyan, A., Reis, H.M., Feitelson, M.A., Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer 13 (2013), 123–135.
96. [96] Alter, H.J., Seeff, L.B., Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 20 (2000), 17–35.
97. [97] Huang, C.F., Chuang, W.L., Yu, M.L., Chronic hepatitis C infection in the elderly. Kaohsiung J. Med. Sci. 27 (2011), 533–537.
98. [98] World Health Organization, Hepatitis B vaccines. Position paper. Weekly Epidemiol. Rec. 40 (2009), 405–420.
99. [99] Ortqvist, A., Blennow, M., Carlsson, R.M., Hanson, L.A., Lindberg, A., Lindqvist, L., Magnusson, M., Nilsson, L., Norlund, A., Nyren, O., Olcen, P., Olin, P., Silfverdal, S.A., Sawe, J., Soderstrom, A., Trollfors, B., Vaccination of children–a systematic review. Acta Paediatr. Suppl. 99 (2010), 1–192.
100. [100] Mathew, J.L., El, D.R., Mathew, P.J., Boxall, E.H., Brok, J., Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status. Cochrane Database Syst. Rev., 2008 CD006481.
101. [101] Cui, F., Li, L., Hadler, S.C., Wang, F., Zheng, H., Chen, Y., Gong, X., Hutin, Y.J., Cairns, K.L., Liang, X., Yang, W., Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992–2005. Vaccine 28 (2010), 5973–5978.
102. [102] Ni, Y.H., Chang, M.H., Wu, J.F., Hsu, H.Y., Chen, H.L., Chen, D.S., Minimization of hepatitis B infection by a 25-year universal vaccination program. J. Hepatol. 57 (2012), 730–735.
103. [103] Chiang, C.J., Yang, Y.W., You, S.L., Lai, M.S., Chen, C.J., Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 310 (2013), 974–976.
104. [104] Sun, Z., Chen, T., Thorgeirsson, S.S., Zhan, Q., Chen, J., Park, J.H., Lu, P., Hsia, C.C., Wang, N., Xu, L., Lu, L., Huang, F., Zhu, Y., Lu, J., Ni, Z., Zhang, Q., Wu, Y., Liu, G., Wu, Z., Qu, C., Gail, M.H., Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 34 (2013), 1800–1805.
105. [105] Tajiri, H., Tanaka, H., Brooks, S., Takano, T., Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers. Cancer Causes Control 22 (2011), 523–527.
106. [106] McMahon, B.J., Bulkow, L.R., Singleton, R.J., Williams, J., Snowball, M., Homan, C., Parkinson, A.J., Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 54 (2011), 801–807.
107. [107] The Gambia Hepatitis Study Group, The Gambia Hepatitis Intervention Study. Cancer Res. 47 (1987), 5782–5787.
108. [108] Mendy, M., Peterson, I., Hossin, S., Peto, T., Jobarteh, M.L., Jeng-Barry, A., Sidibeh, M., Jatta, A., Moore, S.E., Hall, A.J., Whittle, H., Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One, 8, 2013, e58029.
109. [109] Viviani, S., Carrieri, P., Bah, E., Hall, A.J., Kirk, G.D., Mendy, M., Montesano, R., Plymoth, A., Sam, O., Van der Sande, M., Whittle, H., Hainaut, P., 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev. 17 (2008), 3216–3223.
110. [110] Sun, Z., Zhu, Y., Stjernsward, J., Hilleman, M., Collins, R., Zhen, Y., Hsia, C.C., Lu, J., Huang, F., Ni, Z., Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study. Cancer Detect. Prev. 15 (1991), 313–318.
111. [111] Qu, C., Chen, T., Fan, C., Zhan, Q., Wang, Y., Lu, J., Lu, L.L., Ni, Z., Huang, F., Yao, H., Zhu, J., Fan, J., Zhu, Y., Wu, Z., Liu, G., Gao, W., Zang, M., Wang, D., Dai, M., Hsia, C.C., Zhang, Y., Sun, Z., Efficacy of neonatal HBV Vaccination on liver cancer and other liver diseases over 30-Year Follow-up of the Qidong Hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med., 11, 2014, e1001774.
112. [112] Institute of Medicine. The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies. 2013, The National Academies Press, Washington, DC.
113. [113] O'Flanagan, D., Cotter, S., Mereckiene, J., Hepatitis B Vaccination in Europe November 2008–March 2009 (VENICE project)., 2009 Available from: http://venice.cineca.org/Report_Hepatitis_B_Vaccination.pdf (accessed on 06.08.2015).
114. [114] World Health Organization. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection. 2014 Available from: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ (accessed on 03.11.2015).
115. [115] National Institute for Health and Care Excellence (NICE). Hepatitis B and C Testing: People at Risk of Infection, NICE Guidelines [PH43]. 2012 Available from: https://www.nice.org.uk/guidance/ph43 (accessed on 05.11.2015).
116. [116] National Institute for Health and Care Excellence (NICE). Hepatitis B (chronic): Diagnosis and Management, NICE Guidelines [CG165]. 2013 Available from: https://www.nice.org.uk/guidance/cg165 (accessed on 05.11.2015).
117. [117] European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 57 (2012), 167–185.
118. [118] European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C. J. Hepatol. 61 (2014), 373–395.
119. [119] LeFevre, M.L., Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Ann. Int. Med. 161 (2014), 58–66.
120. [120] Liaw, Y.F., Impact of therapy on the outcome of chronic hepatitis B. Liver Int. 33:Suppl. 1 (2013), 111–115.
121. [121] Schiff, E.R., Lee, S.S., Chao, Y.C., Kew, Y.S., Bessone, F., Wu, S.S., Kryczka, W., Lurie, Y., Gadano, A., Kitis, G., Beebe, S., Xu, D., Tang, H., Iloeje, U., Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol. 9 (2011), 274–276.
122. [122] Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M., Washington, M.K., Germanidis, G., Flaherty, J.F., Schall, R.A., Bornstein, J.D., Kitrinos, K.M., Subramanian, G.M., McHutchison, J.G., Heathcote, E.J., Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381 (2013), 468–475.
123. [123] Chang, T.T., Liaw, Y.F., Wu, S.S., Schiff, E., Han, K.H., Lai, C.L., Safadi, R., Lee, S.S., Halota, W., Goodman, Z., Chi, Y.C., Zhang, H., Hindes, R., Iloeje, U., Beebe, S., Kreter, B., Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52 (2010), 886–893.
124. [124] Wong, G.L., Yiu, K.K., Wong, V.W., Tsoi, K.K., Chan, H.L., Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol. Ther. 32 (2010), 1059–1068.
125. [125] Jin, H., Pan, N., Mou, Y., Wang, B., Liu, P., Long-term effect of interferon treatment on the progression of chronic hepatitis B: Bayesian meta-analysis and meta-regression. Hepatol. Res. 41 (2011), 512–523.
126. [126] Petersen, J., Buti, M., Considerations for the long-term treatment of chronic hepatitis B with nucleos(t) ide analogs. Expert Rev. Gastroenterol. Hepatol. 6 (2012), 683–694.
127. [127] Sherman, M., Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma?. Hepatology 58 (2013), 18–20.
128. [128] Fernandez-Rodriguez, C.M., Gutierrez-Garcia, M.L., Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. World J. Gastrointest. Pharmacol. Ther. 5 (2014), 175–182.
129. [129] Kimer, N., Dahl, E.K., Gluud, L.L., Krag, A., Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open, 2, 2012.
130. [130] Singal, A.G., Volk, M.L., Jensen, D., Di Bisceglie, A.M., Schoenfeld, P.S., A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin. Gastroenterol. Hepatol., 8, 2010 280–288.e1.
131. [131] van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., Duarte-Rojo, A., Heathcote, E.J., Manns, M.P., Kuske, L., Zeuzem, S., Hofmann, W.P., de Knegt, R.J., Hansen, B.E., Janssen, H.L., Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
132. [132] Morgan, R.L., Baack, B., Smith, B.D., Yartel, A., Pitasi, M., Falck-Ytter, Y., Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann. Int. Med. 158 (2013), 329–337.
133. [133] Fried, M.W., Buti, M., Dore, G.J., Flisiak, R., Ferenci, P., Jacobson, I., Marcellin, P., Manns, M., Nikitin, I., Poordad, F., Sherman, M., Zeuzem, S., Scott, J., Gilles, L., Lenz, O., Peeters, M., Sekar, V., De, S.G., Beumont-Mauviel, M., Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 58 (2013), 1918–1929.
134. [134] Jacobson, I.M., Dore, G.J., Foster, G.R., Fried, M.W., Radu, M., Rafalsky, V.V., Moroz, L., Craxi, A., Peeters, M., Lenz, O., Ouwerkerk-Mahadevan, S., De La Rosa, G., Kalmeijer, R., Scott, J., Sinha, R., Beumont-Mauviel, M., Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384 (2014), 403–413.
135. [135] Manns, M., Marcellin, P., Poordad, F., de Araujo, E.S., Buti, M., Horsmans, Y., Janczewska, E., Villamil, F., Scott, J., Peeters, M., Lenz, O., Ouwerkerk-Mahadevan, S., De La Rosa, G., Kalmeijer, R., Sinha, R., Beumont-Mauviel, M., Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384 (2014), 414–426.
136. [136] Forns, X., Lawitz, E., Zeuzem, S., Gane, E., Bronowicki, J.P., Andreone, P., Horban, A., Brown, A., Peeters, M., Lenz, O., Ouwerkerk-Mahadevan, S., Scott, J., De La Rosa, G., Kalmeijer, R., Sinha, R., Beumont-Mauviel, M., Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 146 (2014), 1669–1679.
137. [137] Zeuzem, S., Berg, T., Gane, E., Ferenci, P., Foster, G.R., Fried, M.W., Hezode, C., Hirschfield, G.M., Jacobson, I., Nikitin, I., Pockros, P.J., Poordad, F., Scott, J., Lenz, O., Peeters, M., Sekar, V., De, S.G., Sinha, R., Beumont-Mauviel, M., Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 146 (2014), 430–441.e6.
138. [138] Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S.C., Schultz, M., Davis, M.N., Kayali, Z., Reddy, K.R., Jacobson, I.M., Kowdley, K.V., Nyberg, L., Subramanian, G.M., Hyland, R.H., Arterburn, S., Jiang, D., McNally, J., Brainard, D., Symonds, W.T., McHutchison, J.G., Sheikh, A.M., Younossi, Z., Gane, E.J., Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368 (2013), 1878–1887.
139. [139] Jacobson, I.M., Gordon, S.C., Kowdley, K.V., Yoshida, E.M., Rodriguez-Torres, M., Sulkowski, M.S., Shiffman, M.L., Lawitz, E., Everson, G., Bennett, M., Schiff, E., Al-Assi, M.T., Subramanian, G.M., An, D., Lin, M., McNally, J., Brainard, D., Symonds, W.T., McHutchison, J.G., Patel, K., Feld, J., Pianko, S., Nelson, D.R., Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368 (2013), 1867–1877.
140. [140] Zeuzem, S., Dusheiko, G.M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R.H., Illeperuma, A., Svarovskaia, E., Brainard, D.M., Symonds, W.T., Subramanian, G.M., McHutchison, J.G., Weiland, O., Reesink, H.W., Ferenci, P., Hezode, C., Esteban, R., Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 370 (2014), 1993–2001.
141. [141] Pawlotsky, J.M., NS5A inhibitors in the treatment of hepatitis C. J. Hepatol. 59 (2013), 375–382.
142. [142] Afdhal, N., Reddy, K.R., Nelson, D.R., Lawitz, E., Gordon, S.C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., Lalezari, J., Younes, Z.H., Pockros, P.J., Di Bisceglie, A.M., Arora, S., Subramanian, G.M., Zhu, Y., Dvory-Sobol, H., Yang, J.C., Pang, P.S., Symonds, W.T., McHutchison, J.G., Muir, A.J., Sulkowski, M., Kwo, P., Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370 (2014), 1483–1493.
143. [143] Kowdley, K.V., Gordon, S.C., Reddy, K.R., Rossaro, L., Bernstein, D.E., Lawitz, E., Shiffman, M.L., Schiff, E., Ghalib, R., Ryan, M., Rustgi, V., Chojkier, M., Herring, R., Di Bisceglie, A.M., Pockros, P.J., Subramanian, G.M., An, D., Svarovskaia, E., Hyland, R.H., Pang, P.S., Symonds, W.T., McHutchison, J.G., Muir, A.J., Pound, D., Fried, M.W., Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370 (2014), 1879–1888.
144. [144] van de Vooren, K., Curto, A., Garattini, L., Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?. Eur. J. Health. Econ. 16 (2015), 341–345.
145. [145] Plummer, M., Franceschi, S., Vignat, J., Forman, D., De Martel, C., Global burden of gastric cancer attributable to Helicobacter pylori. Int. J. Cancer 136 (2015), 487–490.
146. [146] Bastos, J., Peleteiro, B., Barros, R., Alves, L., Severo, M., de Fatima, P.M., Pinto, H., Carvalho, S., Marinho, A., Guimaraes, J.T., Azevedo, A., La, V.C., Barros, H., Lunet, N., Sociodemographic determinants of prevalence and incidence of Helicobacter pylori infection in Portuguese adults. Helicobacter 18 (2013), 413–422.
147. [147] Zagari, R.M., Fuccio, L., Wallander, M.A., Johansson, S., Fiocca, R., Casanova, S., Farahmand, B.Y., Winchester, C.C., Roda, E., Bazzoli, F., Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano–Monghidoro study. Gut 57 (2008), 1354–1359.
148. [148] World Gastroenterology Organisation Global Guidelines, Helicobacter pylori in Developing Countries. 2010 Available from: http://www.worldgastroenterology.org/guidelines/global-guidelines/helicobacter-pylori-in-developing-countries/helicobacter-pylori-in-developing-countries-english (accessed on 05.11.2015).
149. [149] Moayyedi, P., Axon, A.T., Feltbower, R., Duffett, S., Crocombe, W., Braunholtz, D., Richards, I.D., Dowell, A.C., Forman, D., Relation of adult lifestyle and socioeconomic factors to the prevalence of Helicobacter pylori infection. Int. J. Epidemiol. 31 (2002), 624–631.
150. [150] Porras, C., Nodora, J., Sexton, R., Ferreccio, C., Jimenez, S., Dominguez, R.L., Cook, P., Anderson, G., Morgan, D.R., Baker, L.H., Greenberg, E.R., Herrero, R., Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control 24 (2013), 209–215.
151. [151] Yim, J.Y., Kim, N., Choi, S.H., Kim, Y.S., Cho, K.R., Kim, S.S., Seo, G.S., Kim, H.U., Baik, G.H., Sin, C.S., Cho, S.H., Oh, B.H., Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 12 (2007), 333–340.
152. [152] Oona, M., Utt, M., Nilsson, I., Uibo, O., Vorobjova, T., Maaroos, H.I., Helicobacter pylori infection in children in Estonia: decreasing seroprevalence during the 11-year period of profound socioeconomic changes. Helicobacter 9 (2004), 233–241.
153. [153] Greenberg, E.R., Park, J.Y., Effectiveness of Helicobacter pylori eradication. Helicobacter working group (2014), I.A.R.C., (eds.) Helicobacter pylori eradication as a strategy for preventing gastric cancer, 2014, International Agency for Research on Cancer (IARC Working Group Reports, No. 8), Lyon, France, 64–71.
154. [154] Ma, J.L., Zhang, L., Brown, L.M., Li, J.Y., Shen, L., Pan, K.F., Liu, W.D., Hu, Y., Han, Z.X., Crystal-Mansour, S., Pee, D., Blot, W.J., Fraumeni, J.F. Jr., You, W.C., Gail, M.H., Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J. Natl. Cancer Inst. 104 (2012), 488–492.
155. [155] Ford, A.C., Forman, D., Hunt, R.H., Yuan, Y., Moayyedi, P., Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ, 348, 2014, g3174.
156. [156] Gisbert, J.P., Greenberg, E.R., Potential regimens for the mass eradication of Helicobacter pylori infection. IARC Helicobacter working group (2014), (eds.) Helicobacter pylori eradication as a strategy for preventing gastric cancer, 2014, International Agency for Research on Cancer (IARC Working Group Reports, No. 8), Lyon, France, 95–110.
157. [157] Malfertheiner, P., Megraud, F., O'Morain, C.A., Atherton, J., Axon, A.T., Bazzoli, F., Gensini, G.F., Gisbert, J.P., Graham, D.Y., Rokkas, T., El-Omar, E.M., Kuipers, E.J., Management of Helicobacter pylori infection–the Maastricht IV/Florence Consensus Report. Gut 61 (2012), 646–664.
158. [158] IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer., 2014, International Agency for Research on Cancer (IARC Working Group Reports, No. 8), Lyon, France Available from: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php (accessed on 03.11.2015).
159. [159] Franceschi, S., Lise, M., Clifford, G.M., Rickenbach, M., Levi, F., Maspoli, M., Bouchardy, C., Dehler, S., Jundt, G., Ess, S., Bordoni, A., Konzelmann, I., Frick, H., Dal, M., Aso, L., Elzi, L., Furrer, H., Calmy, A., Cavassini, M., Ledergerber, B., Keiser, O., Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br. J. Cancer 103 (2010), 416–422.
160. [160] Joint United Nations Programme on HIV/AIDS (UNAIDS). 2012-UNAIDS Report on the Global AIDS Epidemic., 2012 Available from: http://www.unaids.org/en/resources/documents/2012/20121120_UNAIDS_Global_Report_2012 (accessed on 03.11.2015).
161. [161] European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS Surveillance in Europe 2013. 2014 Available from: http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1217 (accessed on 03.11.2015).
162. [162] Clifford, G., Bertisch, B., Franceschi, S., Clifford et al. respond to biological and clinical insights from epidemiologic research into HIV, HPV, and anal cancer. Am. J. Epidemiol. 178 (2013), 888–889.
163. [163] Chou, R., Selph, S., Dana, T., Bougatsos, C., Zakher, B., Blazina, I., Korthuis, P.T., Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. Ann. Int. Med. 157 (2012), 706–718.
164. [164] World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2013 Available from: http://www.who.int/hiv/pub/guidelines/arv2013/en/ (accessed on 03.11.2015).
165. [165] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. 2015 Available from: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/ (accessed on 03.11.2015).
166. [166] U.S. Department of Health and Human Services. Guide for HIV/AIDS Clinical Care–2014 Edition. 2014 Available from: http://hab.hrsa.gov/deliverhivaidscare/2014guide.pdf (accessed on 03.11.2015).
167. [167] Moyer, V.A., Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement. Ann. Int. Med. 159 (2013), 51–60.